We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-4.22%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$740M
AUM Growth
+$30.5M
Cap. Flow
-$240M
Cap. Flow %
-32.47%
Top 10 Hldgs %
67%
Holding
218
New
54
Increased
59
Reduced
50
Closed
36

Top Buys

Rank Stock Value
1
BTBT icon
Bit Digital
BTBT
+$40.7M
2
SLAI
SOLAI Ltd ADS
SLAI
+$15.2M
3
VRPX
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
+$7.02M
4
FLUX icon
Flux Power
FLUX
+$6.05M
5
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$5.87M

Top Sells

Rank Stock Value
1
LNAI
Lunai Bioworks
LNAI
+$7.71M
2
ATOS icon
Atossa Therapeutics
ATOS
+$4.06M
3
ATER icon
Aterian
ATER
+$4M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$2.95M
5
RDHL
Redhill Biopharma
RDHL
+$2.34M

Sector Composition

Rank Sector Weight
1 Miscellaneous 77.12%
2 Healthcare 8.81%
3 Financials 5.55%
4 Technology 3.48%
5 Industrials 1.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GROMW
176
DELISTED
Grom Social Enterprises Inc. Warrants
GROMW
$32K ﹤0.01%
982
– –
FEED
177
ENvue Medical Inc
FEED
$857K
– –
0
– –
TRX icon
178
PUT
TRX Gold Corp
TRX
$396M
$20K ﹤0.01%
404
-1,164
-74% -$527
ITP icon
179
PUT
IT Tech Packaging
ITP
$2.68M
$17K ﹤0.01%
25
-98
-80% -$411
TRX icon
180
TRX Gold Corp
TRX
$396M
$6K ﹤0.01%
+12,213
New +$5.53K
ATER icon
181
Aterian
ATER
$12M
– –
-36,083
Closed -$4M
ATOS icon
182
Atossa Therapeutics
ATOS
$24.5M
– –
-69,732
Closed -$4.06M
BCTX
183
Briacell Therapeutics
BCTX
$30.7M
– –
-1,307
Closed -$1.04M
BIIB icon
184
Biogen
BIIB
$32B
– –
-4,000
Closed -$1.39M
BTCT icon
185
BTC Digital
BTCT
$22.6M
– –
-1,223
Closed -$712K
CLRB icon
186
Cellectar Biosciences
CLRB
$21.9M
– –
-1,422
Closed -$508K
CVM icon
187
CEL-SCI Corp
CVM
$26.7M
– –
-4,843
Closed -$1.26M
HEPA
188
CALL
DELISTED
Hepion Pharmaceuticals
HEPA
– –
-1
Closed -$220K
HEPA
189
PUT
DELISTED
Hepion Pharmaceuticals
HEPA
– –
-1
Closed -$194K
JOB icon
190
GEE Group
JOB
$25.5M
– –
-700,000
Closed -$401K
NMAD
191
Nomad Power Solutions
NMAD
$60.7M
– –
-6,551
Closed -$199K
LIXTW
192
DELISTED
Lixte Biotechnology Warrants
LIXTW
– –
-140,089
Closed -$107K
MGNX icon
193
CALL
MacroGenics
MGNX
$260M
– –
-92
Closed -$247K
MGNX icon
194
PUT
MacroGenics
MGNX
$260M
– –
-182
Closed -$489K
PPBT
195
Purple Biotech
PPBT
$2.73M
– –
-253
Closed -$245K
RDHL
196
CALL
Redhill Biopharma
RDHL
$3.53M
– –
0
– -$117K
RDHL
197
Redhill Biopharma
RDHL
$3.53M
– –
-340
Closed -$2.34M
SHIP icon
198
Seanergy Maritime Holdings
SHIP
$396M
– –
-65,000
Closed -$728K
DCOY
199
Decoy Therapeutics
DCOY
$1.78M
– –
-7
Closed -$264K
TVTX icon
200
Travere Therapeutics
TVTX
$5.81B
– –
-10,042
Closed -$147K
5 6 7
8
9

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2021 Portfolio in Review

As of Q3 2021, Sabby Management held 218 positions worth $740M, up 4.3% from $709M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $240M in Q3 2021, closing 36 positions and reducing 50 holdings. Its most notable exit was Atossa Therapeutics, an estimated $4.06M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 77% of assets, down from 81% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Sabby Management opened a new position in Bit Digital worth $30.5M.

  • Sabby Management's largest Q3 2021 buy was Bit Digital: 4,216,310 shares worth $30.5M.
  • Sabby Management added most to Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021, an estimated $7.02M increase.
  • Sabby Management's biggest Q3 2021 reduction was Lunai Bioworks, cutting an estimated $7.71M.
  • Sabby Management fully exited Atossa Therapeutics in Q3 2021, selling an estimated $4.06M.
  • Sabby Management's ten largest holdings make up 67% of its $740M portfolio in Q3 2021.
  • Sabby Management opened 54 new positions and closed 36 in Q3 2021.
  • Sabby Management's portfolio value rose 4.3% quarter-over-quarter to $740M.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.